Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
86
Recruiting, any sponsor type, condition "influenza"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed1,692
86 trials
Showing 1 to 25, recently updated first.
- pH1N1 Blinded Challenge StudyRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07110532 · 90 participants (planned) · Start Sep 10, 2025 · Primary completion Mar 29, 2027
Drug: A/Arkansas/08/2020 (pH1N1) · For: Influenza
Sites: Baltimore, Maryland; Durham, North Carolina
- BPL-1357 Against H1N1 Influenza Virus ChallengePivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07215858 · 129 participants (planned) · Start Nov 25, 2026 · Primary completion Mar 1, 2028
Drug: BPL-1357 IM; BPL-1357 IN · For: Influenza; Human
Sites: Bethesda, Maryland; Galveston, Texas
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07169318 · 78 participants (planned) · Start Sep 16, 2025 · Primary completion May 1, 2027
Drug: VNT-101 · For: Influenza
Sites: Overland Park, Kansas
- Clinical Trial to Evaluate the Immunogenicity and Safety of GC3114B in Adults Aged 65 Years or OlderPivotal-lookingRecruiting
GC Biopharma CorpIndustry
NCT07883928 · 1,806 participants (planned) · Start Oct 12, 2026 · Primary completion Mar 2028
Drug: vaccination of GC3114B; Vaccination of Efluelda · For: Influenza A, Influenza B; Influenza Vaccination
Sites: Seoul, South Korea
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaPivotal-lookingRecruiting
Boryung Biopharma Co., Ltd.Industry
NCT07943390 · 348 participants (planned) · Start Nov 2026 · Primary completion Apr 2027
Drug: BRC-201; Placebo · For: Influenza
Sites: Seoul, South Korea
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household ContactsPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06094010 · 1,100 participants (planned) · Start Nov 22, 2023 · Primary completion May 11, 2027
Drug: Baloxavir Marboxil · For: Influenza
Sites: Birmingham, Alabama; Harrisburg, Arkansas; Miami, Florida · 52 sites in all
- A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese ParticipantsPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07827599 · 325 participants (planned) · Start Oct 16, 2026 · Primary completion Apr 30, 2027
Drug: Baloxavir marboxil; Placebo · For: Influenza, Human; Respiratory Tract Infections; Post-exposure Prophylaxis
Sites: Guangzhou, China; Zunyi, China; Mianyang, China · 20 sites in all
- A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)Pivotal-lookingRecruiting
Sinovac Biotech Co., LtdIndustry
NCT07832201 · 150 participants (planned) · Start Oct 20, 2026 · Primary completion Feb 2027
Drug: Anflu®; Vaxigrip® · For: Influenza
Sites: Changsha, China; Chengdu, China; Chongqing, China · 6 sites in all
- A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)Pivotal-lookingRecruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT07300085 · 710 participants (planned) · Start Nov 8, 2025 · Primary completion Dec 31, 2026
Drug: Fluzone® High-Dose (HD) influenza vaccine · For: Healthy Participants
Sites: Phoenix, Arizona; Glendale, California; Miami, Florida · 15 sites in all
Stanford UniversityAcademic, hospital or other
NCT04579588 · 230 participants (planned) · Start Oct 29, 2020 · Primary completion Apr 2028
Drug: Flu shot · For: Corona Virus Infection; Flu Vaccine; Immunity
Sites: Palo Alto, California
- A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and OlderRecruiting
Ab&B Bio-tech Co., Ltd.JSAcademic, hospital or other
NCT07933458 · 7,000 participants (planned) · Start Sep 4, 2026 · Primary completion Mar 31, 2027
Drug: subunit influenza vaccine · For: Influenza
Sites: Ganzhou, China
- A Study of Updated mRNA Seasonal Influenza VaccinesPivotal-lookingRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07884175 · 200 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 7, 2026
Drug: mRNA-1010; Licensed High-Dose Seasonal Influenza Vaccine · For: Seasonal Influenza
Sites: Tucson, Arizona; Lenexa, Kansas; Louisville, Kentucky · 4 sites in all
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07111078 · 56 participants (planned) · Start Aug 27, 2025 · Primary completion Aug 18, 2027
Drug: VRC-FLUMOS0122-00-VP · For: Influenza Prevention; Pandemic Influenza Prevention
Sites: Bethesda, Maryland
Yale UniversityAcademic, hospital or other
NCT05291676 · 96 participants (planned) · Start Nov 6, 2023 · Primary completion May 2029
Drug: Fluzone; Fluad · For: Influenza
Sites: New Haven, Connecticut
Sung-Han KimAcademic, hospital or other
NCT07926217 · 60 participants (planned) · Start Nov 2, 2026 · Primary completion Dec 31, 2027
Drug: High-dose inactivated influenza vaccine; Standard-dose inactivated influenza vaccine · For: Hematologic Malignancy; Influenza
Sites: Seoul, South Korea
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy ChildrenRecruiting
ModernaTX, Inc.Moderna (MRNA)
NCT07870330 · 96 participants (planned) · Start Oct 7, 2026 · Primary completion Dec 7, 2027
Drug: mRNA-1010; Fluarix Trivalent · For: Seasonal Influenza
Sites: Modesto, California; Aurora, Colorado; Minneapolis, Minnesota · 6 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
Washington University School of MedicineAcademic, hospital or other
NCT07914673 · 40 participants (planned) · Start Sep 25, 2026 · Primary completion Feb 1, 2027
Drug: Trivalent inactivated influenza vaccine; RabAvert · For: Healthy Adult Participants; Age 65 and Older; Age 18 to 40 and 1 more
Sites: St Louis, Missouri
Henry M. Jackson Foundation for the Advancement of Military MedicineAcademic, hospital or other
NCT07287137 · 54 participants (planned) · Start Nov 12, 2025 · Primary completion Sep 2027
Drug: Pfizer-BioNTech mRNA COVID-19 vaccine; Novavax recombinant protein vaccine · For: COVID -19; COVID - 19; COVID 19 and 5 more
Sites: Bethesda, Maryland
- Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza VaccinationPivotal-lookingRecruiting
University of Missouri-ColumbiaAcademic, hospital or other
NCT07910266 · 220 participants (planned) · Start Oct 2026 · Primary completion Feb 2027
Drug: Egg-Based Inactivated Influenza Vaccine; Cell-Based Inactivated Influenza Vaccine · For: Immunology
Sites: Columbia, Missouri
- Intradermal Influenza VaccinationPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT07908329 · 139 participants (planned) · Start Oct 1, 2026 · Primary completion May 2029
Drug: Fluzone® Quadrivalent; Fluzone® Quadrivalent and 1 more · For: Vaccine Reaction
Sites: New Haven, Connecticut
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05624450 · 3,527 participants (planned) · Start Dec 13, 2022 · Primary completion Nov 4, 2027
Drug: Tozorakimab; Placebo · For: Viral Lung Infection and Acute Respiratory Failure
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 473 sites in all
- High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) RecipientsPivotal-lookingRecruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT05947071 · 312 participants (planned) · Start Sep 26, 2024 · Primary completion Jul 1, 2027
Drug: Standard Dose Quadrivalent Inactivated Influenza Vaccine; High Dose Quadrivalent Inactivated Influenza Vaccine · For: Immunization; Infection; Transplantation Infection; Influenza
Sites: Stanford, California; Atlanta, Georgia; Chicago, Illinois · 11 sites in all
- INfluenza VaccInation To Mitigate typE 1 DiabetesPivotal-lookingRecruiting
Aarhus University HospitalAcademic, hospital or other
NCT05585983 · 100 participants (planned) · Start Dec 14, 2022 · Primary completion May 1, 2027
Drug: Vaxigrip Tetra Sanofi Pasteur Europe · For: Diabetes Mellitus, Type 1
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 10 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.